



On-line Supplemental Table S1. Two-way ANOVA analysis

genotype	treatment	UAE ($\mu\text{g/day}$)	CCr ($\mu\text{l/min}$)	open capillary volume (%)	FPW (nm)	number of slits (per 1 mm GBM)	prepro ET-1 mRNA	ET _A R mRNA
WT	Ad-Fc	27 $\pm$ 4	480 $\pm$ 40	49.8 $\pm$ 0.9	627 $\pm$ 73	1643 $\pm$ 204	1.00 $\pm$ 0.09	1.00 $\pm$ 0.17
eNOS ^{-/-}	Ad-Fc	28 $\pm$ 5	410 $\pm$ 48	51.8 $\pm$ 1.6	769 $\pm$ 69	1323 $\pm$ 125	0.82 $\pm$ 0.04	1.65 $\pm$ 0.35
WT	Ad-sFlt-1	174 $\pm$ 23	452 $\pm$ 63	26.6 $\pm$ 1.6	764 $\pm$ 37	1328 $\pm$ 68	2.74 $\pm$ 0.31	3.44 $\pm$ 0.65
eNOS ^{-/-}	Ad-sFlt-1	467 $\pm$ 74	126 $\pm$ 29	13.1 $\pm$ 1.8	2334 $\pm$ 233	455 $\pm$ 46	5.00 $\pm$ 0.89	6.04 $\pm$ 1.13
<i>p</i> (ANOVA)								
treatment (T)		<0.0001	0.0036	<0.0001	0.0004	<0.0001	<0.0001	0.017
genotype (G)		<0.0001	0.0005	0.0012	0.0003	<0.0001	0.028	<0.0001
T x G		<0.0001	0.014	<0.0001	0.0017	0.0099	0.01	0.14

UAE: urinary albumin excretion. CCr: creatinine clearance. FPW: foot process width. Data are expressed as mean $\pm$ SEM (n $\geq$ 5 each). T x G designates the *P* values of the interaction between treatment and genotype.



On-line Supplemental Figure S1. Excess ET-1 worsens renal phenotypes of preeclampsia in WT sFlt-1 mice. A and B: Urinary albumin excretion and creatinine clearance 6 days after administration of both ET-1 and Ad sFlt-1 to WT mice compared to those of WT sFlt-1 mice without ET-1 administration and of eNOS sFlt-1 mice. Data are expressed as mean $\pm$ SEM. $n \geq 4$ each group. C: Representative photos of glomeruli from WT sFlt-1 mice, WT sFlt-1 mice with ET-1, and eNOS^{-/-} sFlt-1 mice. PAS stain. Bars, 20µm.



On-line Supplemental Figure S2. Excess ET-1 causes podocyte foot process effacement in WT sFlt-1 mice. Arrow: the loss of glomerular endothelial fenestration; broken arrows: effacement of foot processes. Bars, 2μm.